New drug shows promise for severe eczema in toddlers

NCT ID NCT07660835

Recruiting now Disease control Sponsor: Galderma R&D Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests a drug called nemolizumab in toddlers aged 6 to 23 months with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams or ointments. The goal is to see how the drug moves through the body, if it is safe, and if it helps control the condition. All children receive the drug, and researchers monitor their blood levels, side effects, and skin improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nemolizumab
What this could lead to: If successful, this could provide a new treatment option for young children with hard-to-control eczema, potentially reducing itching and skin inflammation.
What could go wrong: This is an early-phase study with only 35 participants, so results may not apply to all children. Side effects are possible, and the drug may not work as well as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE-TO-SEVERE ATOPIC DERMATITIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Texas Dermatology and Laser Specialist-San Antonio
RECRUITING

San Antonio, Texas, 78218, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.